secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001683168-23-006962
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares
--------------------------------------------------------------------------------

- Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.
- Transaction expected to close Q4 2023, subject to shareholder approvals and other conditions, including Oragenics having ≥$5M cash at close.
- ONP-002 completed Phase 1 trial; Phase 2 preparation underway; animal studies show reduced swelling, inflammation, oxidative stress.
- Odyssey management members intend to join Oragenics post-close to continue development.
- Odyssey retains other assets and operations; Oragenics expands into neurological therapeutics via intranasal delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/0001683168-23-006962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer